#### 1 Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a

#### 2 randomised, double-blinded, phase 2/3, placebo-controlled trial

3 Sergio Fragoso-Saavedra, Isaac Núñez, Belem M. Audelo-Cruz, Sarahi Arias-Martínez, Daniel

- 4 Manzur-Sandoval, Alejandro Quintero-Villegas, H. Benjamín García-González, Sergio L. Carbajal-
- 5 Morelos, Sergio Ponce de León-Rosales, José Gotés-Palazuelos, José A. Maza-Larrea, Yanink Caro-
- 6 Vega, Isabella Batina, León Islas-Weinstein, David A. Iruegas-Nunez, Juan J. Calva, Pablo F.
- 7 Belaunzarán-Zamudio, Juan Sierra-Madero, José C. Crispín, Sergio I. Valdés-Ferrer.
- 8

## 9 Affiliations:

Plan de Estudios Combinados en Medicina (MD/PhD Program), Facultad de Medicina, Universidad
Nacional Autónoma de México, Mexico City, Mexico (S Fragoso-Saavedra MD); Internal Medicine

12 Residency Training Program, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,

13 Mexico City, Mexico (I Núñez MD, A Quintero-Villegas MD, HB García-González MD, SL Carbajal-

14 Morelos MD); Departamento de Neurología y Psiquiatría (S Fragoso-Saavedra MD, BM Audelo-Cruz

15 MD, S Arias-Martínez MD, I Batina MD, DA Iruegas-Nunez MD, SI Valdés-Ferrer MD, PhD);

16 Educación Médica (S Ponce de León-Rosales MD); Medicina (J Gotés-Palazuelos MD, MSc);

17 Inmunología y Reumatología (JC Crispín MD, PhD); Infectología (S Fragoso-Saavedra MD, Y Caro-

18 Vega PhD, JJ Calva MD; MSc, J Sierra-Madero MD, SI Valdés-Ferrer MD, PhD) and Patología

19 Experimental (L Islas-Weinstein MD; PhD), Instituto Nacional de Ciencias Médicas y Nutrición

20 Salvador Zubirán, Mexico City, Mexico; Escuela Superior de Medicina, Instituto Politécnico Nacional,

21 Mexico City, Mexico (BM Audelo-Cruz MD); Instituto Nacional de Cardiología Ignacio Chávez, Mexico

22 City, Mexico (D Manzur-Sandoval MD, JA Maza-Larrea MD); Escuela de Medicina y Ciencias de la

23 Salud, Tecnologico de Monterrey, Monterrey, Mexico (DA Iruegas-Nunez MD, JC Crispín MD, PhD);

24 Bethesda, MD, USA (PF Belaunzarán-Zamudio MD, MSc); Center for Biomedical Science, Feinstein

25 Institutes for Medical Research, Manhasset, NY, USA. (SI Valdés-Ferrer MD, PhD).

- 26
- 27 Address correspondence to: Sergio I. Valdés-Ferrer, Departamento de Neurología y Psiquiatría,
- 28 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Phone:
- 29 +52(55)5487-0900, ext. 4177. Email: sergio.valdesf@incmnsz.mx

#### 31 Summary

Background: Hospitalised patients with severe COVID-19 have an increased risk of developing acute respiratory distress syndrome (ARDS) and death from severe systemic inflammatory response. Acetylcholine modulates the acute inflammatory response through a neuro-immune mechanism known as the inflammatory reflex. Pyridostigmine, an acetylcholine-esterase inhibitor, increases the half-life of endogenous ACh, reducing lung and systemic inflammation in murine sepsis. This trial aimed to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19.

39 Methods: We performed a parallel-group, multicentre, double-blinded, placebo-controlled,

randomised clinical trial in two COVID-19-designated hospitals in Mexico City, Mexico. Adult (≥ 18-40 41 vear-old), hospitalised patients with confirmed SARS-CoV-2 infection based on a positive RT-PCR test 42 in a respiratory specimen, a computed tomography compatible with pneumonia, as well as requiring 43 supplementary oxygen were included. Patients were randomly assigned (1:1) to receive oral 44 pyridostigmine (60 mg per day) or placebo for a maximum of 14 days. The intention-to-treat analysis 45 included all the patients who underwent randomisation. The primary endpoint was the composite 46 outcome of initiation of IMV and 28-day all-cause mortality. The trial is registered in ClinicalTrials.gov, 47 NCT04343963.

Findings: Between May 5, 2020, and Jan 29, 2021,188 participants were randomly assigned to
placebo (n=94) or pyridostigmine (n=94). The composite outcome occurred in 22 (23·4%) *vs.* 11
(11·7%) participants, respectively (hazard ratio 0·46, 95% CI 0·22-0·96, *p*=0·03). The most frequent
adverse event was diarrhoea (5 [5·3%] in the pyridostigmine group *vs* 3 [3·2%] in the placebo group).
Most of the adverse events were mild to moderate, with no serious adverse events related to
pyridostigmine.

Interpretation: Our data indicates that the addition of pyridostigmine to standard treatment reduces
significantly the fatality rate among patients hospitalized for severe COVID-19.

- 56 **Funding:** Consejo Nacional de Ciencia y Tecnología, México.
- 57

#### 58 INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus 59 disease 2019 (COVID-19)<sup>1</sup>, is a novel pathogen first identified in late 2019 that reached pandemic 60 proportions within weeks after the first cases were reported<sup>2</sup>. COVID-19 represents a heterogeneous 61 62 disease that ranges from asymptomatic to lethal. Patients with severe COVID-19 develop a severe systemic inflammatory response<sup>3</sup> and acute respiratory distress syndrome<sup>4</sup>, that may progress to 63 multiple-organ failure and death<sup>5,6</sup>. Although the factors that determine the clinical expression of 64 65 COVID-19 are not completely understood, an exuberant deregulated inflammatory response plays a 66 central pathogenic role in patients with severe disease. In concordance, pharmacological strategies 67 aimed at reducing inflammation have been able to moderately reduce disease outcomes. Dexamethasone, reduced mortality among patients requiring supplementary oxygen or ventilatory 68 69 support. However, its use was accompanied by important and frequent adverse effects such as 70 hyperglycaemia, psychosis, and gastrointestinal hemorrhage<sup>7</sup>. Tocilizumab, a recombinant humanised 71 anti-interleukin (IL)-6 receptor monoclonal antibody, reduced the need for mechanical ventilation, as 72 well as mortality, in patients with severe COVID-19, regardless of the degree of respiratory support 73 needed<sup>8</sup>. Finally, remdesivir, an antiviral, alone or in combination with baricitinib, a selective inhibitor of Janus kinases 1 and 2, accelerated recovery and reduced in-hospital stay<sup>9,10</sup>. These three 74 75 approaches may have increased survival rates, but severe COVID-19 remains an unsolved problem. in particular in countries with low vaccine coverage. 76

The central nervous system regulates the inflammatory response via the release of acetylcholine by
the vagus nerve, reducing the production of inflammatory mediators, through the *inflammatory reflex*<sup>11</sup>.
Choline-acetyltransferase (ChAT)-expressing T cells modulate inflammation via *in situ* release of
acetylcholine<sup>12</sup> and this effect is critical in reducing viremia in animal models of viral infection<sup>13</sup>.
Pyridostigmine, an acetylcholinesterase inhibitor (i-ACh-e), increases acetylcholine (ACh) half-life by
inhibiting its peripheral degradation. Pyridostigmine is used for the symptomatic treatment of
myasthenia gravis<sup>14</sup> and as pre-exposure prophylaxis for nerve gas poisoning<sup>15</sup>. In human

84	immunodeficiency virus (HIV)-1 infection, pyridostigmine modulates T-cell activation and reduces
85	circulating inflammatory markers <sup>16–18</sup> . Recent experimental evidence indicates that, in murine
86	lipopolysaccharide (LPS)-induced systemic inflammation, pyridostigmine reduces lung neutrophil
87	recruitment, as well as levels of tumour necrosis factor and IL-6 in the bronchioalveolar lavage <sup>19</sup> .
88	Pyridostigmine has not yet been evaluated as immuno-modulator in acute severe human inflammatory
89	conditions; nonetheless, indirect clinical and experimental evidence suggests that pyridostigmine may
90	be effective in reducing the inflammation in patients with COVID-19.

- 91 Our main aim was to evaluate the efficacy of pyridostigmine as an adjunct therapy to reduce the
- 92 incidence of critical illness or death in hospitalized adults with severe COVID-19.

#### 93 METHODS

## 94 Study design and participants

- 95 We performed a double-blinded, placebo-controlled, parallel group randomised, bicentric clinical trial
- 96 at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), and Instituto
- 97 Nacional de Cardiología Ignacio Chávez (INCICh), two COVID-19-designated Hospitals in Mexico
- 98 City, Mexico. Adult (≥18-year-old) hospitalised patients with confirmed SARS-CoV-2 infection,
- 99 documented by a positive RT-PCR test for SARS-CoV-2 RNA in a respiratory specimen
- 100 (nasopharyngeal or nasal swab), an imaging study compatible with pneumonia, and at least one risk
- 101 factor for requiring IMV or dying (Figure 1), were invited to participate. The full list of inclusion,
- 102 exclusion and elimination criteria has been published<sup>20</sup>.
- 103 All participants provided written informed consent. The clinical study protocol was approved by the
- 104 Ethics in Human Research Committees of both study centres (approval identifier: INF-3323-20-21-1).

# 105 Randomisation and masking

- 106 Patients were randomised in a 1:1 ratio, with a parallel assignment and unstratified block-
- 107 randomisation approach using a publicly available online resource (<u>www.randomizer.org</u>) to receive
- 108 pyridostigmine or placebo besides standard medical treatment. Preparing, packing, masking, and

109 labelling active and placebo pills, as well as overseeing drug dispensing was performed by trained 110 pharmacy staff at both study centres. Pyridostigmine and placebo pills were unidentifiable from one 111 another. Participants were enrolled and assigned to treatment by investigators. Throughout the study, 112 participants, site staff and investigators were masked to the treatment allocation until completion of the 113 intervention and follow-up phases. There was no formalised evaluation of masking.

## 114 **Procedures and outcomes**

The primary outcome was a composite of invasive mechanical ventilation (IMV) or death in the 28 days following randomisation (Fig. 1), and frequency of specific adverse events. Prespecified secondary outcomes included: (a) the length of in-hospital days after randomisation; (b) hospital discharge by day-28; (c) among those who required IMV, the number of days with, and the survival rate after IMV; (d) failure to complete treatment as expected due to adverse events (other than the primary composite outcome).

121 Participants were allocated (1:1 ratio) to receive, in addition to standard medical treatment, either oral 122 pyridostigmine at a dose of 60 mg/day P.O. or a matching placebo (pharmaceutical-grade starch) until 123 the occurrence of (a) any of the prespecified outcomes, (b) hospital discharge, or (c) 14 in-hospital 124 days. We collected demographic information from participants at baseline, including age, sex, and 125 comorbidities (including diabetes mellitus, hypertension, obesity, cardiovascular disease, lung 126 disease, or other chronic medical conditions). Participants already discharged from the hospital by day 127 28, including those who were transferred to another facility, were contacted by telephone to assess 128 their vital and functional status.

Adverse events (AEs) were collected using data obtained from the medical health records of each
study participant. The events were evaluated and coded using the Medical Dictionary and Regulatory
Activities (MedDRA) version 24.0 browser and the severity of the AEs was assessed by the National
Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

Although not used throughout the study, unblinding was allowed in case of severe adverse events at
the request of either the treating group of physicians or the external Data and Safety Monitoring Board
(DSMB). The study was conducted in two parts, as already described<sup>20</sup>: a phase 2 aimed at
determining safety (5 May to 4 July 2020), followed by a phase 3 aimed at evaluating the effect -or
lack thereof- of pyridostigmine in patients with severe COVID-19 (5<sup>th</sup> July 2020, to 30<sup>th</sup> January 2021).
Participants in both phases were included in the analyses of outcomes.

#### 139 Statistical analysis

The trial was planned and approved in March 2020, shortly after the first case of COVID-19 was 140 141 diagnosed in Mexico. At that time, we relied on limited information about clinical outcomes in these 142 patients. Thus, we calculated a sample size of 436 participants considering an event rate of 25% in 143 the control group, a 10% absolute reduction (40% relative reduction) in the primary outcome as 144 clinically significant, and a power of 80% to detect a difference in the primary outcome using a twosided significance level of  $\alpha = 0.05^{20}$ . However, we pre-stipulated that the sample size would be 145 adjusted according to interim analyses. The first participant was recruited on May 5<sup>th</sup>, 2020. The 146 147 DSMB performed an interim analysis after the first 44 participants (22 per group, 10% of the calculated sample) to evaluate safety on July 4<sup>th</sup>, 2020; a second interim analysis was conducted on December 148 149 7<sup>th</sup>, 2020 including 28-day outcomes on 100 participants (50 per group). Due to an observed 150 difference in the primary outcome between groups (still blinded to investigators, but unblinded to the 151 DSMB), as well as difficulty recruiting new participants due to a reduction in eligible patients and a 152 swell in competing studies, we decided to stop the trial after 188 participants had been recruited (94 in 153 each group). Considering the same  $\alpha$ =0.05, we recalculated the statistical power of the obtained 154 sample with the observed difference between groups (an absolute reduction of 11.7% and relative reduction of 50%), which resulted in ~85%. 155

We conducted an intention-to-treat analysis for the primary outcome that included all the patients who underwent randomisation. As secondary outcomes, we assessed between-group differences of mechanical ventilation and death with or without IMV. Patients that had not developed an outcome by

- day 28 were censored at day 29. The magnitude of the effect of pyridostigmine on the primary
- 160 outcome was estimated with a hazard ratio (HR) and its 95% confidence interval (CI) calculated with
- 161 Cox proportional hazard model and the difference between groups was compared with log-rank test,
- as were IMV, and death with or without IMV, and discharge home although these secondary outcomes
- 163 were not pre-specified in the study protocol. We built Kaplan Meier survival curves to plot the
- 164 cumulative incidence of the primary outcome up to day-28. Statistical analysis was conducted with
- 165 Prism GraphPad software, version 9.1.0 (GraphPad Software, San Diego, CA), and R version 4.0.0.
- 166 This trial is registered in ClinicalTrials.gov, NCT04343963.

#### 167 Role of the funding source

- The funder of the study had no role in study design, data collection, data analysis, data interpretation,or writing of the report.
- 170
- 171 RESULTS

# 172 Patients

173 Between May 5, 2020, and Jan 29, 2021, we assessed for eligibility 334 patients, of whom 201 174 accepted to participate; of those, thirteen patients were excluded for the following reasons: five 175 withdrew consent after signing but before randomisation; four were transferred to a different facility 176 before randomisation; three required IMV before randomisation, and one was diagnosed with lung 177 cancer (one of our exclusion criteria) during the initial assessment, therefore withdrawn from the study 178 before randomisation. In total, 188 participants underwent randomisation, 94 in each group, all of 179 whom received at least one dose of the assigned intervention. Enrolment and randomisation are 180 shown in Figure 1. Baseline demographic and clinical characteristics were balanced between groups 181 (Table 1).

The median age of the patients was 52 years (interquartile range [IQR], 44 to 64 years), and 59.6 %
were male. The most common pre-existing conditions at enrolment were diabetes and hypertension

184 (**Table 1**). The imbalance of obesity proportion between groups appeared to be clinically relevant (53.2% vs. 33%, affecting predominantly the pyridostigmine group), so we performed an  $X^2$  test which 185 186 also showed a statistically significant difference (p=0.005). There were no relevant differences in the 187 rest of the baseline characteristics between groups, including the number of patients who received 188 dexamethasone or tocilizumab as part of in-hospital medical management (**Table 1**). All participants 189 were hypoxemic and received supplementary oxygen as part of in-patient management. The median 190 interval from symptom onset to randomisation was 10 days (IQR, 9 to 12 days). The median interval 191 from hospital admission to randomisation was 2 days (IQR, 1 to 3 days). Dexamethasone was 192 administered to 140 participants (69 on the pyridostigmine group and 71 on the placebo group). 193 Tocilizumab was administered to 10 participants (5 on the pyridostigmine group, and 5 on the placebo

194 group). None of the participants received Remdesivir.

# 195 **Primary outcome**

- 196 Thirty-three participants met the primary outcome by day 28; 11 (11.7%) in the pyridostigmine group
- and 22 (23.4%) in the control group (HR 0.47, 95% CI 0.23-0.95, p=0.03) (**Figure 2**). IMV was
- initiated in 6 (6.4%) patients in the pyridostigmine group and 7 (7.5%) in the placebo group (HR 0.81,
- 199 95%Cl 0·27-2·42, p=0·7) (Figure 3a-b). The median duration of IMV was 15 days (IQR, 10 to 23) in
- 200 the pyridostigmine group and 17 days (IQR, 7 to 39) in the placebo group. The survival rate after IMV
- 201 was 66.7% (four patients) in the pyridostigmine group and 42.9% (three patients) in the placebo group.
- 202

# 203 Secondary outcomes

A total of 26 patients died by day 28, 7 in the pyridostigmine group and 19 in the placebo group (HR 0.33, 95%CI 0.14-0.81, p=0.01) **(Figure 3c)**. All of the deaths in the pyridostigmine group occurred in the study centre while three in the placebo group happened after the patients had been transferred to another centre. The median duration of in-hospital stay after randomisation (censored at day 29) was 5 days (IQR, 3 to 10 days) in the pyridostigmine group and 5 days (IQR, 3 to 8 days) in the placebo

group. The twenty-eight-day hospital discharge rate was 90.4% (85 patients) in the pyridostigmine
group and 75.5% (71 patients) in the control group (Table 2 and Fig. 3). As expected, the use of
dexamethasone was adequately balanced between study groups (69 in the pyridostigmine group and
71 in the placebo group). In the placebo group, the composite primary endpoint occurred more
commonly among patients that did not receive dexamethasone (35% vs. 20%, respectively). In
contrast, in the pyridostigmine group, an opposite trend was observed (8% vs.13%, respectively).
However, the study was not designed, nor has the power, to address drug synergism.

216 We collected and analysed 83 AEs throughout the study. Overall, 45 (47.9%) patients of the

217 pyridostigmine group and 38 (40.4%) of the placebo group had at least one adverse drug reaction.

218 The rate and severity of AEs were similar between both groups (Supplemental Tables 1-3).

219 One hundred and sixty-six (88-3%) participants received experimental treatment (i.e., pyridostigmine 220 or placebo) as assigned during their in-hospital stay; 22 (11.7%) discontinued treatment early, nine 221 (9.5%) in the pyridostigmine group, and 13 (13.8%) in the placebo group. Two participants in each 222 group discontinued trial medication due to an adverse event other than the principal outcome: one 223 patient presented nausea and one mild abdominal pain in the pyridostigmine group (known adverse 224 effects of pyridostigmine), and in the placebo group one patient had pyrosis and one presented 225 diarrhoea. The remaining patients discontinued trial medication after being transferred to another 226 facility (Figure 1). Drug adherence was supervised by a physician or nurse, and each administration 227 was confirmed in the electronic records; therefore, among the 166 participants who received 228 medication as assigned, adherence was 100%.

Finally, as obesity status differed between study groups, we performed a sensitivity analysis with a Cox proportional hazards model adjusted for obesity status. We excluded 10 patients (four from the pyridostigmine group and six from the control group) that had no information on obesity status (of which only one had a primary outcome) for this sensitivity analysis, obtaining an adjusted HR of 0.42 (95% CI 0.19-0.91, p=0.05) for the primary outcome, 0.78 (95%CI 0.24-2.54, p=0.3) for IMV, and 0.32 (95%CI 0.13-0.77, p=0.03) for death.

235

#### 236 **DISCUSSION**

Here, we show that added to standard care, pyridostigmine is associated with decreased IMV and mortality in patients hospitalized for severe COVID-19. This was driven by a decrease in all-cause mortality in the pyridostigmine group compared to that of the placebo group (by 12.7 percentage points). IMV was an infrequent outcome, which explains the lack of difference when analysing this outcome by itself. Also, the adjunct use of pyridostigmine increased the probability of being discharged from the hospital alive within 28 days.

243 Early reports estimated mortality rates as elevated as 49% for hospitalized patients with severe COVID-19<sup>21</sup>. Although the in-hospital mortality rate has been declining throughout the pandemic, 244 recent studies still show rates ranging from 20 to over 40%<sup>22-25</sup>. For instance, the risk of death still 245 246 exceeded 20% in the dexamethasone and tocilizumab arms of the RECOVERY trial, being the only 247 two treatments that have shown a reduction in mortality<sup>7,24</sup>. Similarly, in the placebo group we 248 observed a 28-day mortality of 20.21%, but a majority had received dexamethasone as part of the 249 standard of care, indicating that, without further intervention, in-hospital mortality of severe COVID-19 250 remains high. The severity and mortality of COVID-19 are mediated by the development of an 251 uncontrolled inflammatory response to infection; elevated levels of proinflammatory cytokines and 252 other immune mediators have been associated with multiorgan failure due to endothelial damage and tissue injury<sup>4,6</sup>. Hence, finding novel immunomodulatory strategies represents a promising strategy to 253 254 reduce the severity and mortality of COVID-19. That, along with the repurposing of drugs with well-255 characterized safety profiles and readily available production lines, might lead to faster development of 256 anti-COVID-19 therapies if proven efficacious in well-designed, randomised clinical trials.

In mammals, the central nervous system has mechanisms to control the inflammatory response.

258 During inflammatory states, the vagus nerve can inhibit the synthesis and release of inflammatory

259 cytokines, thereby reducing both local damage and mortality secondary to severe systemic

260 inflammation in murine models as diverse as sepsis, ischemia, and reperfusion damage, or obesity<sup>26–</sup>

261 <sup>29</sup>. The vagus nerve can be stimulated electrically and chemically. Chemical stimulation using cholinergic agonists has shown promising effects in murine and cellular models of inflammation<sup>29,30</sup>. 262 263 Acetylcholine esterase inhibitors (i-ACh-e) are a family of drugs used regularly by millions of patients, 264 including older adults with Alzheimer's disease and other dementias, as well as patients with myasthenia gravis and dysautonomia<sup>14,31–34</sup>. These drugs inhibit the enzymatic degradation of 265 endogenous ACh, resulting in greater bioavailability and, therefore, increasing the possibility of binding 266 267 to both nicotinic and muscarinic receptors. In addition to the approved uses of i-ACh-e in human pathology, there is evidence in various murine models of their efficacy in experimental sepsis and 268 severe inflammatory response<sup>19,27,28,30</sup>, suggesting that i-ACh-e drugs may exert a potential 269 270 immunomodulatory effect in patients with severe systemic inflammatory response syndrome.

271 Regarding safety concerns, at the used dose of pyridostigmine (60 mg/day), the rate of adverse

events we observed was 47.9% -none severe- and not different from the observed rate in the placebogroup (40.4%).

The reduction in mortality in patients with severe COVID-19 who received pyridostigmine may be due to an immunomodulatory effect, however, its precise biological effect in this novel disease remains to be studied. Different immunomodulatory strategies have been tested that have sought to selectively inhibit the biological activity of certain pro-inflammatory cytokines, such as IL-6<sup>35</sup>; however, the global inhibition of several of them by pharmacologically stimulating the inflammatory reflex could be more effective, which is the effect sought with the administration of pyridostigmine. We are currently working in understanding the mechanism behind our observed effect.

Our study has important limitations. The originally planned sample size could not be achieved. Still, a significant difference was observed because of a greater than expected effect. Also, some patients requiring IMV could probably not receive it because of either, a pre-existing living will; last-minute patient (or proxy) refusal of intubation; or, intermittently throughout the study period, lack of availability of critical care beds<sup>22,23</sup>. Our primary outcome included initiation, but not necessarily the requirement, of IMV. This is reflected by the fact that the bulk of the primary outcome was due to deaths among

287 participants who did not receive IMV, most likely related to lack of critical care space. Thus, our results 288 may not be generalizable to settings that do not have this problem. While most baseline 289 characteristics were evenly balanced between groups, obesity (a known predictor of adverse 290 outcomes in COVID-19) was randomly more prevalent in the pyridostigmine group; this imbalance that 291 in principle plays against pyridostigmine strengthens our observed outcomes. As a proof-of-concept, 292 this study needs to be replicated or refuted in independent clinical trials. Also, at this point, our results 293 cannot be extrapolated to patients with less severe disease, or those already receiving IMV, without 294 prior verification in clinical trials. Finally, medium-term outcomes (90 days) will be reported at a later 295 time point.

296 The strengths of the study include that it is a double-blinded, placebo-controlled, multicentric

randomised clinical trial that evaluated a therapeutic intervention that is inexpensive, has a positive pharmacological profile, is safe, and is widely available as a generic drug. The demographics of our study population, including age and comorbid conditions, are representative of a large group of the underserved population worldwide (particularly across the Americas), a population in urgent need of safe, effective, life-saving, and affordable treatments for severe COVID-19.

In conclusion, we present evidence to support the use of pyridostigmine as an add-on treatment to
 standard medical care in patients hospitalized for severe COVID-19. Our data indicate that this
 inexpensive and readily available drug may significantly reduce mortality without imposing relevant
 adverse effects.

306

#### 307 Contributors

JCC, PFBZ, JSM and SIVF designed the study. SFS, SIVF, and IN wrote the manuscript. JCC, JSM
and JJC contributed to the writing of the article. SFS did the block randomisation. SFS, BMAC, SAM,
DMS, IN, HBGG, AQV, SLCM and SIVF contributed to the recruitment of participants. JAML and JGP
evaluated the safety of the pharmacological intervention. SFS, BMAC, DMS, DAIN, IB, and LIW

- 312 contributed to data gathering and entry. SFS, IN, SIVF analysed all data. PFBZ, YCV, and SPdeLR
- 313 provided additional statistical support. SFS, IN, and SIVF accessed and verified the trial data. All
- authors approved the submission of this article.
- 315

# 316 Data sharing

- 317 De-identified individual participant data and all protocol documents can be provided to others upon
- 318 reasonable request on approval of a written request to the corresponding author.
- 319

#### 320 **Declaration of interests**

SI Valdés-Ferrer via Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán appears as
 inventor for a repurpose patent for the use of pyridostigmine in COVID-19. If granted, we aim to
 release the patent to the public domain.

324

325 Acknowledgements: This study was funded by Consejo Nacional de Ciencia y Tecnología, Mexico 326 (COVID-19 Fund [F0005-2020-01]; grant 311790), to SIV-F]. The authors are grateful to Kevin J. 327 Tracey, M.D., for his insight and suggestions that positively impacted this manuscript; to Claudia 328 Quiñones, B.Ch. and, Elia Criollo-Mora, B.Ch. for preparing, packing, masking, labelling, and 329 dispensing treatments: to Dr Virginia Pascual-Ramos for providing ethical and statistical 330 recommendations throughout the study; and to Dr Florencia Rosetti and the Immunopathology Lab, 331 INCMNSZ for their logistic support. Lastly, the authors wish to dedicate this manuscript to all medical 332 and surgical residents and fellows across the world for their generous and selfless work during the 333 COVID-19 pandemic. We understand that this is not the kind of residency training you dreamed of, but your work has, time and again, made a difference and every day you make us all proud. 334

# **Table 1. Clinical and demographical characteristics of patients at baseline.**

Variables	All	Pyridostigmine	Placebo
<b>2</b> (24)	(N=188)	(N=94)	(N=94)
Sex - no. (%)	-	-	-
Male	112 (59.6)	56 (59.6)	56 (59.6)
Female	76 (40·4)	38 (40.4)	38 (40-4)
Age	-	-	-
Median (IQR) - yr	52 (44-64)	51 (43-63)	54 (46-66)
Previous coexisting			
disease - no. (%)	-	-	-
Diabetes	68 (36-2)	33 (35.1)	35 (37.2)
Hypertension	66 (35.1)	33 (35.1)	33 (35.1)
Heart disease	4 (2.1)	2 (2.1)	2 (2.1)
Chronic lung disease	8 (4.3)	6 (6.4)	2 (2.1)
Obesity**	81 (43.1)	50 (53-2)	31 (33)
Median BMI (IQR) –	29 (26.5-33)	30.25 (26.5-33.4)	28.1 (26.5-31.45)
kg/m <sup>2</sup> **	20 (20 0 00)	00 20 (20 0 00 4)	201 (200 01 40)
Median time (IQR)			
from symptom onset	10 (0 12)	10 (8-11)	10 (0-13)
to randomisation -	10 (3-12)	10 (0-11)	10 (9-13)
days			
Median time (IQR)			
from admission to	2 (1-3)	2 (1-2)	2 (1-3)
randomisation – days			
Other			
immunomodulators			
used by medical team	-	-	-
– no. (%)			
Dexamethasone	140 (74.5)	69 (73-4)	71 (75.5)
Tocilizumab	10 (5.3)	5 (5.3)	5 (5.3)

337 **\*\*BMI** information was not available for 10 patients, four in the pyridostigmine group and six in

338 the placebo group.

339

# **Table 2. Primary and secondary outcomes by day 28.**

Outcomes	All (N=188)	Pyridostigmine (N=94)	Placebo (N=94)	HR (95% CI)	P-value
Primary outcome					
Invasive mechanical ventilation or death – no. (%)	33 (17.5%)	11 (11.7%)	22 (23·4%)	0.46 (0.23-0.95)	0.03
Secondary outcomes					
Invasive mechanical ventilation – no- (%)	13 (6.9%)	6 (6.3%)	7 (7.4%)	0.81 (0.27-2.42)	0.7
Median time (IQR) in ICU with invasive mechanical ventilation - days	17 (11-23)	15 (15-21)	17 (12-30)	-	-
Survival after IMV — no. (%)	7 (53.8)	4 (66%)	3 (42.9)	-	-
Death - no. (%)	26 (13.8%)	7 (7.4%)	19 (20.2%)	0.33 (0.14-0.81)	0.01
*Median time (IQR) from randomisation to discharge home – days	5 (3-9)	5 (3-10)	5 (3-8)	-	-
Discharge home by day 28 – no. (%)	156 (82.9)	85 (90.4)	71 (75.5)	1.13 (0.82-1.55)	0.4
Adverse events - no. (%)	83 (44-1)	45 (47.9)	38 (40-4)	-	
Failure to complete treatment due to adverse effects – no. (%)	4 (2)	2 (2)	2 (2)	-	-

342 \*For time to discharge home in patients that were transferred, the time from randomisation until

343 discharge home from the hospital that they were transferred to was used. Two patients did not have

this information available but were discharged home alive. For them, the date of transfer was used.

345 Patients that were still in the hospital on day 28 were censored on day 29.

# 347 FIGURE LEGENDS

- 348 **Figure 1. Enrolment and randomisation.**
- 349 **Figure 2. Time to Mechanical Ventilation or Death by Day 28.**

# 350 Figure 3. Time to Mechanical Ventilation, Death or Discharge Home by Day 28 as Separate

- 351 **Outcomes.** A) IMV as the primary outcome; B) death as the primary outcome; and, C) Discharge
- 352 home as the primary outcome. Hazard ratios were calculated with Cox proportional hazards models
- and p-values were obtained with a log-rank test. In the case of IMV as the primary outcome, deaths
- 354 without IMV were censored. In the case of death as the primary outcome, IMV was not considered.

## 356 References

- 357 1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in China,
  358 2019. *N Engl J Med* 2020; **382**: 727–33.
- Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html (accessed
   May 15, 2021).
- 361 3 Xu Z, Shi L, Wang Y, *et al.* Pathological findings of COVID-19 associated with acute respiratory
   362 distress syndrome. *Lancet Respir Med* 2020; **8**: 420–2.
- Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus
  in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19
  based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; 46:
  846–8.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider
   cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033–4.
- 370 7 Horby P, Lim WS, Emberson J, *et al.* Dexamethasone in Hospitalized Patients with Covid-19. *N* 371 *Engl J Med* 2021; **384**: 693–704.
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19
  (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. *Lancet*2021; **397**: 1637–45.
- Beigel JH, Tomashek KM, Dodd LE, *et al.* Remdesivir for the Treatment of Covid-19 Final
  Report. *N Engl J Med* 2020; **383**: 1813–26.
- Kalil AC, Patterson TF, Mehta AK, *et al.* Baricitinib plus Remdesivir for Hospitalized Adults with
  Covid-19. *N Engl J Med* 2021; **384**: 795–807.

- Borovikova L V., Ivanova S, Zhang M, *et al.* Vagus nerve stimulation attenuates the systemic
   inflammatory response to endotoxin. *Nature* 2000; **405**: 458–62.
- Rosas-Ballina M, Olofsson PS, Ochani M, *et al.* Acetylcholine-synthesizing T cells relay neural
   signals in a vagus nerve circuit. *Science (80- )* 2011; **334**. DOI:10.1126/science.1209985.
- Cox MA, Duncan GS, Lin GHY, *et al.* Choline acetyltransferase–expressing T cells are required
   to control chronic viral infection. *Science (80- )* 2019; **363**: 639–44.
- Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic
   strategies. *Lancet Neurol* 2015; **14**: 1023–36.
- Keeler JR, Hurst CG, Dunn MA. Pyridostigmine Used as a Nerve Agent Pretreatment Under
   Wartime Conditions. *JAMA J Am Med Assoc* 1991; **266**: 693–5.
- 389 16 Valdés-Ferrer SI, Crispín JC, Belaunzarán PF, Cantú-Brito CG, Sierra-Madero J, Alcocer-

390 Varela J. Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in

patients infected by HIV. *AIDS Res Hum Retroviruses* 2009; **25**. DOI:10.1089/aid.2008.0257.

- Valdés-Ferrer SI, Crispín JC, Belaunzarán-Zamudio PF, *et al.* Add-on Pyridostigmine enhances
   CD4+ T-cell recovery in HIV-1-infected immunological non-responders: A proof-of-concept
   study. *Front Immunol* 2017; 8: 1–6.
- Robinson-Papp J, Nmashie A, Pedowitz E, *et al.* The effect of pyridostigmine on small intestinal
   bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic
   neuropathies. *J Neurovirol* 2019; 25: 551–9.
- Bricher Choque PN, Vieira RP, Ulloa L, *et al.* The Cholinergic Drug Pyridostigmine Alleviates
   Inflammation During LPS-Induced Acute Respiratory Distress Syndrome . Front. Pharmacol. .
   2021; 12: 966.

401 20 Fragoso-Saavedra S, Iruegas-Nunez DA, Quintero-Villegas A, et al. A parallel-group,

402 multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the

- 403 efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical
- 404 ventilation in adults with severe SARS-CoV-2 inf. *BMC Infect Dis* 2020; **20**: 765.
- Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease
  2019(COVID-19) outbreak in China. *Jama* 2020; **2019**: 10.1001/jama.2020.2648.
- 407 22 Rossman H, Meir T, Somer J, *et al.* Hospital load and increased COVID-19 reñated mortality in
  408 Israel. *Nat Commun* 2021; **12**: 1–7.
- Olivas-Martínez A, Cárdenas-Fragoso JL, Jiménez JV, *et al.* In-hospital mortality from severe
  COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact
  of hospital saturation. *PLoS One* 2021; **16**: e0245772.
- de Souza FSH, Hojo-Souza NS, Batista BD de O, da Silva CM, Guidoni DL. On the analysis of
  mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major
  Brazilian database. *PLoS One* 2021; **16**: e0248580.
- 415 25 Núñez I, Priego-Ranero ÁA, García-González HB, *et al.* Common hematological values predict
  416 unfavorable outcomes in hospitalized COVID-19 patients. *Clin Immunol* 2021; **225**: 108682.
- 417 26 Yeboah MM, Xue X, Duan B, *et al.* Cholinergic agonists attenuate renal ischemia-reperfusion
  418 injury in rats. *Kidney Int* 2008; **74**: 62–9.
- 419 27 Satapathy SK, Ochani M, Dancho M, et al. Galantamine alleviates inflammation and other

420 obesity-associated complications in high-fat diet-fed mice. *Mol Med* 2011; **17**.

- 421 DOI:10.2119/molmed.2011.00083.
- 422 28 Zaghloul N, Addorisio ME, Silverman HA, *et al.* Forebrain cholinergic dysfunction and systemic
  423 and brain inflammation in murine sepsis survivors. *Front Immunol* 2017; 8.
- 424 DOI:10.3389/fimmu.2017.01673.
- Lehner KR, Silverman HA, Addorisio ME, *et al.* Forebrain cholinergic signaling regulates innate
  immune responses and inflammation. *Front Immunol* 2019; **10**: 1–11.

- 427 30 Rosas-Ballina M, Valdés-Ferrer SI, Dancho ME, et al. Xanomeline suppresses excessive pro-
- 428 inflammatory cytokine responses through neural signal-mediated pathways and improves
- 429 survival in lethal inflammation. *Brain Behav Immun* 2015; **44**: 19–27.
- 430 31 Mayeux R. Clinical practice. Early Alzheimer's disease. *N Engl J Med* 2010; **362**: 2194–201.
- 431 32 Querfurth HW, Laferla FM. Alzheimer's Disease. *N Engl J Med* 2018; **326**: 329–44.
- 432 33 O'Brien JT, Thomas A. Vascular dementia. *Lancet* 2015; **386**: 1698–706.
- 433 34 Singer W, Sandroni P, Opfer-Gehrking TL, *et al.* Pyridostigmine treatment trial in neurogenic
  434 orthostatic hypotension. *Arch Neurol* 2006; **63**: 513–8.
- 435 35 Salama C, Han J, Yau L, *et al.* Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
- 436 *N Engl J Med* 2021; **384**: 20–30.
- 437
- 438
- 439

# Figure 1. Enrollment and randomization









